Stay updated on Pembrolizumab in Recurrent PCNSL Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent PCNSL Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer’s site revision label was updated from v3.7.2 to v3.8.0; the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T16:13:09.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A site-wide banner announces the NIH website transition and says that NIH content may use “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T17:08:27.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:35:43.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T22:35:27.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study details and navigation with an access-block message. This indicates the study record is currently inaccessible on this page.
    Difference
    18%
    Check dated 2026-09-20T20:33:20.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    A new site revision label v3.6.6 was added, replacing the previous v3.6.5. This indicates a small deployment to the ClinicalTrials.gov interface.
    Difference
    0.1%
    Check dated 2026-08-30T11:29:07.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent PCNSL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.